Abstract library

14 results for "Jäger".
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#974 Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma
Introduction: Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Leonidas Apostolidis
#1038 Co-Expression of Somatostatin and CXCR4 Receptors as Targets for Diagnostics and Treatment in Intestinal Neuroendocrine Neoplasms.
Introduction: Somatostatin receptors (SSTR) are widely distributed in well-differentiated neuroendocrine tumors (NET) and serve as primary targets for diagnostics and treatment. An overexpression of the chemokine receptor CXCR4, in contrast, is considered to be present mainly in highly proliferative and advanced carcinomas.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Keywords: sstr
#1094 Experience with Bevacizumab in Neuroendocrine Tumors
Introduction: Bevacizumab has shown promising activity in neuroendocrine tumors (NET) in combination with a multitude of other substances.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. med. Leonidas Apostolidis
#1095 Efficacy of Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma
Introduction: Therapeutic options for metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC) which is often considered to show a biological behavior similar to NEC.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. med. Leonidas Apostolidis
#1302 Differential Somatostatin and CXCR4 Chemokine Receptor Expression in Primary Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) and Their Metastases
Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, where they serve as molecular targets for different imaging and treatment modalities. The chemokine receptor CXCR4, in contrast, is present mainly in highly proliferative and advanced tumors.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
#1465 Assocation Between miRNAs and HDACs in Pancreatic Neuroendocrine Tumors
Introduction: Epigenetic factors are essentially involved in carcinogenesis, tumor promotion and chemo resistance with their major key players of miRNAs and histone deacetylases (HDACs). As shown by own theoretical databank analysis, the crosstalk between miRNAs and HDACs are relevant in different human chronic diseases and cancerogenic pathways.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Prof. Dr. Daniel Neureiter
#1510 Prognosis and Treatment Outcomes of Patients with Mixed Adenoneuroendocrine Carcinoma (MANEC)
Introduction: Mixed adenoneuroendocrine carcinomas (MANEC) are rare tumors, commonly treated in analogy to adenocarcinomas (AC) or neuroendocrine carcinomas (NEC) without systematic data regarding response to therapy.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Leonidas Apostolidis
#1912 Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms
Introduction: Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to be asymptomatic and SREs are considered rare. The role of ART in preventing SREs in NEN has not been investigated so far.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: Dr. med. Leonidas Apostolidis